A股異動 | 焦作萬方(000612.SZ)復牌漲停 公司或將變更為有實控人的企業
格隆匯6月3日丨焦作萬方(000612.SZ)曾於5月27日開始停牌,停牌前已連續三個交易日漲停。今日復牌繼續漲停,現報5.79元,暫成交8.2億元,最新總市值69億元。焦作萬方昨日晚間披露定增方案稱,公司擬募集資金總額不超過12億元用於補充流動資金或償還公司債務,發行價格為3.51元/股。發行對象為公司第一大股東和泰安成及正才控股。發行後,和泰安成東將持有公司28.32%股權,仍將是公司的第一大股東,其持股數量將大幅領先於公司其他股東,公司或將變更為一家有控股股東及實際控制人的企業。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.